Prodrugs for the Treatment of Neglected Diseases
Recently, World Health Organization (WHO) and Medicins San Frontieres (MSF) proposed a classification of diseases as global, neglected and extremely neglected. Global diseases, such as cancer, cardiovascular and mental (CNS) diseases represent the targets of the majority of the R&D efforts of ph...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2008-03-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/13/3/616 |
| _version_ | 1797481079498604544 |
|---|---|
| author | Man Chin Chung Elizabeth Igne Ferreira Jean Leandro Santos Jeanine Giarolla Daniela Gonçales Rando Adélia Emília Almeida Priscila Longhin Bosquesi Renato Farina Menegon Lorena Blau |
| author_facet | Man Chin Chung Elizabeth Igne Ferreira Jean Leandro Santos Jeanine Giarolla Daniela Gonçales Rando Adélia Emília Almeida Priscila Longhin Bosquesi Renato Farina Menegon Lorena Blau |
| author_sort | Man Chin Chung |
| collection | DOAJ |
| description | Recently, World Health Organization (WHO) and Medicins San Frontieres (MSF) proposed a classification of diseases as global, neglected and extremely neglected. Global diseases, such as cancer, cardiovascular and mental (CNS) diseases represent the targets of the majority of the R&D efforts of pharmaceutical companies. Neglected diseases affect millions of people in the world yet existing drug therapy is limited and often inappropriate. Furthermore, extremely neglected diseases affect people living under miserable conditions who barely have access to the bare necessities for survival. Most of these diseases are excluded from the goals of the R&D programs in the pharmaceutical industry and therefore fall outside the pharmaceutical market. About 14 million people, mainly in developing countries, die each year from infectious diseases. From 1975 to 1999, 1393 new drugs were approved yet only 1% were for the treatment of neglected diseases [3]. These numbers have not changed until now, so in those countries there is an urgent need for the design and synthesis of new drugs and in this area the prodrug approach is a very interesting field. It provides, among other effects, activity improvements and toxicity decreases for current and new drugs, improving market availability. It is worth noting that it is essential in drug design to save time and money, and prodrug approaches can be considered of high interest in this respect. The present review covers 20 years of research on the design of prodrugs for the treatment of neglected and extremely neglected diseases such as Chagas’ disease (American trypanosomiasis), sleeping sickness (African trypanosomiasis), malaria, sickle cell disease, tuberculosis, leishmaniasis and schistosomiasis. |
| first_indexed | 2024-03-09T22:09:22Z |
| format | Article |
| id | doaj.art-636b91f683504073bca22e1c5ff53396 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-09T22:09:22Z |
| publishDate | 2008-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-636b91f683504073bca22e1c5ff533962023-11-23T19:34:15ZengMDPI AGMolecules1420-30492008-03-0113361667710.3390/molecules13030616Prodrugs for the Treatment of Neglected DiseasesMan Chin Chung0Elizabeth Igne Ferreira1Jean Leandro Santos2Jeanine Giarolla3Daniela Gonçales Rando4Adélia Emília Almeida5Priscila Longhin Bosquesi6Renato Farina Menegon7Lorena Blau8Lapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, BrazilLAPEN – Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos em Endemias Tropicais, Departamento de Farmácia, Faculdade de Ciências Farmacêuticas – USP/SP, R. Prof. Lineu Prestes, 580, B-13S,Cidade Universitária,BrazilLapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, BrazilLAPEN – Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos em Endemias Tropicais, Departamento de Farmácia, Faculdade de Ciências Farmacêuticas – USP/SP, R. Prof. Lineu Prestes, 580, B-13S,Cidade Universitária,BrazilLAPEN – Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos em Endemias Tropicais, Departamento de Farmácia, Faculdade de Ciências Farmacêuticas – USP/SP, R. Prof. Lineu Prestes, 580, B-13S,Cidade Universitária,BrazilLapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, BrazilLapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, BrazilLapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, BrazilLapdesf - Laboratório de Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas - UNESP Rodovia Araraquara-Jaú Km 1, 14801-902, BrazilRecently, World Health Organization (WHO) and Medicins San Frontieres (MSF) proposed a classification of diseases as global, neglected and extremely neglected. Global diseases, such as cancer, cardiovascular and mental (CNS) diseases represent the targets of the majority of the R&D efforts of pharmaceutical companies. Neglected diseases affect millions of people in the world yet existing drug therapy is limited and often inappropriate. Furthermore, extremely neglected diseases affect people living under miserable conditions who barely have access to the bare necessities for survival. Most of these diseases are excluded from the goals of the R&D programs in the pharmaceutical industry and therefore fall outside the pharmaceutical market. About 14 million people, mainly in developing countries, die each year from infectious diseases. From 1975 to 1999, 1393 new drugs were approved yet only 1% were for the treatment of neglected diseases [3]. These numbers have not changed until now, so in those countries there is an urgent need for the design and synthesis of new drugs and in this area the prodrug approach is a very interesting field. It provides, among other effects, activity improvements and toxicity decreases for current and new drugs, improving market availability. It is worth noting that it is essential in drug design to save time and money, and prodrug approaches can be considered of high interest in this respect. The present review covers 20 years of research on the design of prodrugs for the treatment of neglected and extremely neglected diseases such as Chagas’ disease (American trypanosomiasis), sleeping sickness (African trypanosomiasis), malaria, sickle cell disease, tuberculosis, leishmaniasis and schistosomiasis.https://www.mdpi.com/1420-3049/13/3/616Tropical neglected diseasesProdrug designAmerican trypanosomisasisAfrican trypanosomiasisMalariaSickle cell disease |
| spellingShingle | Man Chin Chung Elizabeth Igne Ferreira Jean Leandro Santos Jeanine Giarolla Daniela Gonçales Rando Adélia Emília Almeida Priscila Longhin Bosquesi Renato Farina Menegon Lorena Blau Prodrugs for the Treatment of Neglected Diseases Molecules Tropical neglected diseases Prodrug design American trypanosomisasis African trypanosomiasis Malaria Sickle cell disease |
| title | Prodrugs for the Treatment of Neglected Diseases |
| title_full | Prodrugs for the Treatment of Neglected Diseases |
| title_fullStr | Prodrugs for the Treatment of Neglected Diseases |
| title_full_unstemmed | Prodrugs for the Treatment of Neglected Diseases |
| title_short | Prodrugs for the Treatment of Neglected Diseases |
| title_sort | prodrugs for the treatment of neglected diseases |
| topic | Tropical neglected diseases Prodrug design American trypanosomisasis African trypanosomiasis Malaria Sickle cell disease |
| url | https://www.mdpi.com/1420-3049/13/3/616 |
| work_keys_str_mv | AT manchinchung prodrugsforthetreatmentofneglecteddiseases AT elizabethigneferreira prodrugsforthetreatmentofneglecteddiseases AT jeanleandrosantos prodrugsforthetreatmentofneglecteddiseases AT jeaninegiarolla prodrugsforthetreatmentofneglecteddiseases AT danielagoncalesrando prodrugsforthetreatmentofneglecteddiseases AT adeliaemiliaalmeida prodrugsforthetreatmentofneglecteddiseases AT priscilalonghinbosquesi prodrugsforthetreatmentofneglecteddiseases AT renatofarinamenegon prodrugsforthetreatmentofneglecteddiseases AT lorenablau prodrugsforthetreatmentofneglecteddiseases |